Rheumatology is branch of medicine that deals with the diagnosis and treatment of disorders of connective tissues and joints, many of which are now known to be immune mediated conditions.
Optimising anti-TNF treatment using biosimilars
Biosimilars are uniquely placed to change clinical practice in the fields of gastroenterology, rheumatology, and dermatology. The adoption of biosimilars can improve patient access to the most appropriate treatment, at the optimum time, to ensure the best possible long-term disease outcomes.
Rheumatic diseases can be caused by trauma, heredity, genetic abnormality, autoimmune disease, or another underlying condition such as cancer. There are more than 150 different types of rheumatic disorders, including arthritis, rheumatoid and osteoarthritis, gout and lupus.
Related news and insights
Based on a completed FDA review of a large randomized safety clinical trial, the FDA has concluded there is an increased risk of serious heart-related events such as heart attack or stroke, cancer, blood clots, and death with the arthritis and ulcerative colitis medicines Xeljanz and Xeljanz XR (tofacitinib).
Bone Therapeutics announced that the Phase III knee osteoarthritis study with its enhanced viscosupplement JTA 004 (hyaluronic acid + analgesic + antiinflammatory) did not meet the primary and consequently the key secondary endpoints. The primary objective of the JTA-004 Phase III study was to demonstrate the efficacy of JTA 004 in reducing osteoarthritic knee pain compared to placebo as measured by the WOMAC pain subscale three months after treatment. A key secondary objective was the comparison between JTA 004 and comparator Hylan G-F 20 in knee pain relief at month 3.
Developed by EPG Health for Medthority in collaboration with Biogen®. This content is intended for healthcare professionals only, and it has been funded and reviewed by Biogen® for scientific accuracy.